Sensory and Neuromotor System Disorders CRO


In vivex is a preclinical Contract Research Organization ( CRO )
specialized in the evaluation of sensory and neuromotor system disorders

About us

World Health Organization alarming data : Sensory and peripheral nervous diseases in expansion. Aging population, food and noisy lifestyles, spontaneous mutations, sedentarism, infections and toxic drugs on the market lead to an increase of sensory and motor degenerative disorders.


Peripheral neuropathy




30 millions of americans suffer from some type of peripheral neuropathy
40% of cancer patients have chemotherapy-induced peripheral neuropathy
422 million people suffer from diabetes and 60-70% diabetics have peripheral neuropathy
Charcot-Marie Tooth disease with a prevalence 1 over 3,000 people
> 50 years old people with strong risk to develop immune peripheral neuropathy



Hearing impairment


900 million people will have disabling hearing loss in 2050
> 65 years old people suffer from disabling hearing loss
466 million people worldwide have disabling hearing loss



Blindness


1.3 billion people live with some form of vision impairment
≈ 80% of all vision impairment globally is considered avoidable
> 50 years old people suffer from severe vision impairment


And there is no fully effective treatment for these disorders


In vivex is a preclinical Contract Research Organization ( CRO ) specialized in the evaluation of sensory and neuromotor system disorders. We offer a comprehensive list of in vitro and in vivo models covering a wide range of indications. Our aim is to facilitate your preclinical drug development by proposing the best models for your needs using a large panel in vivo and in vitro techniques in the field of hearing, blindness and neuromotor disorders


The strength of in vivex is based on the existence of four preclinical platforms


  • Pharmacokinetics platform
  • Ophthalmology platform
  • Hearing platform
  • Motor and sensory system platform

These services, unique in the world, make In vivex a partner of choice for collaborative projects. In vivex increases the probability of new pharmacological candidate success, improving the quality of results and regulatory reports and securing development times. See Testimonials